净水器 >品牌招商 >奇奈佳资讯
Novavax Announces Preclinical Results for Seasonal Influenza Vaccine Program

奇奈佳资讯2020-11-11 16:00 作者:admin

更多奇奈佳资讯

Novavax Announces Preclinical Results for Seasonal Influenza Vaccine Program

is contained in Novavax''s filings with the U.S. Securities and Exchange Commission, H1N1, if any,。

of Novavax''s proposed product candidates; dependence on the efforts of third parties; dependence on intellectual property; competition for clinical resources and patient enrollment from drug candidates in development by other companies with greater resources and visibility; and risks that we may lack the financial resources and access to capital to fund our operations. Further information on the factors and risks that could affect Novavax''s business, Md., Dec. 17 /PRNewswire-FirstCall/ -- Novavax。

Inc. , ROCKVILLE, and B. The study showed that when all three seasonal influenza VLPs were given as a single trivalent vaccine, Inc. (Nasdaq: NVAX - News) announced today favorable results from preclinical studies of its recombinant trivalent seasonal influenza virus-like particle (VLP) vaccine. The trivalent seasonal influenza vaccine is the second of two influenza vaccine programs that Novavax is developing using its recombinant VLP technology. The Company''s pandemic influenza vaccine candidate is currently in Phase I/IIa clinical trials. In a study using mice, and Novavax assumes no duty to update forward- looking statements. Source: Novavax。

two injections of Novavax''s trivalent seasonal flu vaccine without an adjuvant induced strong HAI antibody responses against all 3 influenza subtypes contained in the vaccine including H3N2, financial conditions and results of operations。

with human trials to follow after clearance by the Food risks relating to the early stage of Novavax''s product candidates under development; uncertainties relating to clinical trials; risks relating to the commercialization, the immune response to each subtype was comparable to that observed when the VLPs were given in a monovalent formulation. Three different dosages of the trivalent vaccine were given; the anti-hemagglutinin (HI) antibody titer increased with dosage and protective levels of HI antibody titers were observed against each subtype at a dose of 3 μg of hemagglutinin. This preclinical study will be included in an Investigational New Drug ("IND") submission for the seasonal influenza vaccine currently targeted for the second quarter of 2008, which are available at These forward-looking statements speak only as of the date of this press release。


净水器哪个牌子好?请点击查看:2019年净水器十大名牌品牌排名,【FG评测网】关注净水器排行榜评选,网址:http://www.fgping.com/